Millennium Management’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-300,000
Closed -$4.69M 6297
2024
Q3
$4.69M Buy
+300,000
New +$5.44M ﹤0.01% 2902
2024
Q1
Sell
-13,800
Closed -$206K 6502
2023
Q4
$206K Sell
13,800
-3,300
-19% -$44.2K ﹤0.01% 5163
2023
Q3
$276K Sell
17,100
-190,800
-92% -$5.5M ﹤0.01% 4976
2023
Q2
$8.63M Buy
+207,900
New +$12.9M ﹤0.01% 2160
2023
Q1
Sell
-22,000
Closed -$1.61M 6701
2022
Q4
$1.61M Buy
+22,000
New +$1.66M ﹤0.01% 3743
2021
Q2
Sell
-15,400
Closed -$2.04M 6913
2021
Q1
$2.04M Buy
+15,400
New +$2.44M ﹤0.01% 3512
2020
Q2
Sell
-4,900
Closed -$330K 4459
2020
Q1
$330K Buy
+4,900
New +$387K ﹤0.01% 3120

Other funds holding NVCR

Millennium Management's NVCR Position: Q1 2026 in Review

Millennium Management reduced its NovoCure (NVCR) stake by 86% in Q1 2026, selling an estimated $6.94M and leaving 91,215 shares worth $994K. The position accounts for ﹤0.01% of the portfolio, ranked #4395.

Millennium Management first reported a position in NVCR in Q4 2015 and has held it in 36 quarters since. The position peaked at $21.9M in Q4 2024. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Millennium Management held 91,215 shares of NovoCure worth $994K as of Q1 2026.
  • Millennium Management sold 555,451 NovoCure shares in Q1 2026, an estimated $6.94M.
  • NovoCure made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4395 holding.
  • Millennium Management first reported a position in NovoCure in Q4 2015 and has held it in 36 quarters since.
  • Millennium Management's NovoCure position peaked at $21.9M in Q4 2024.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.